E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Medulloblastoma: Child brain cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10066594 |
E.1.2 | Term | Medulloblastoma recurrent |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10027107 |
E.1.2 | Term | Medulloblastoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of Part 1 (dose-escalation phase) of this trial is to explore the tolerability of up to 2 cycles of intracerebroventricular 177Lu-DTPA-omburtamab treatment in pediatric and adolescent patients with recurrent or refractory medulloblastoma. The MTD and/or the RP2D for Part 2 will be determined. The primary objective of Part 2 (cohort-expansion phase) of this trial is to establish a safety profile of repeated dosing of 177Lu-DTPA-omburtamab in pediatric and adolescent patients with recurrent or refractory medulloblastoma.
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of Part 1 (dose-escalation phase) are: •to evaluate the absorbed radiation doses to CSF and blood of 177Lu- DTPA-omburtamab after intracerebroventricular administration •to evaluate organ dosimetry of 177Lu-DTPA-omburtamab •to evaluate the PK profile of 177Lu-DTPA-omburtamab The secondary objectives of Part 2 (cohort-expansion phase) are: •to evaluate the PK profile of 177Lu-DTPA-omburtamab •to evaluate the investigator-assessed response •to evaluate the investigator-assessed DoR •to evaluate PFS •to evaluate overall survival OS. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients must satisfy all of the following criteria at the Screening Visit, unless otherwise stated: 1. Histologically confirmed diagnosis of medulloblastoma. 2. SHH, Group 3, or Group 4 according to World Health Organization 2016 classification. 3. Recurrent or refractory to frontline therapy, defined as: a. For Part 1 only: Recurrent (maximum of 2 recurrences) or refractory to frontline therapy. Prior frontline or second-line therapy may involve surgery, craniospinal irradiation, stereotactic radiosurgery, and multi-agent chemotherapy regimens. b. For Part 2 only: Recurrent (maximum of 1 recurrence) or refractory to frontline therapy. Patients with recurrent disease must have received second-line chemotherapy for progressive disease. Prior frontline or second-line therapy may involve surgery, craniospinal irradiation, stereotactic radiosurgery, and multiagent chemotherapy regimens. 4. Have refractory disease, focal or multifocal recurrent disease, or pure leptomeningeal disease. Cytological or radiographic remission is allowed; however, not simultaneously. 5. Performance status score of 50 to 100, both inclusive, on the Lansky [<16 years] or Karnofsky [≥16 years] scales. 6. Aged 3 to 19 years, both inclusive, at the time of the first planned dose of trial treatment. 7. Life expectancy of at least 3 months, as judged by the investigator. 8. Acceptable hematological status prior to first dosing (hematological support is allowed if administered at least 1 week before administration of 177Lu-DTPA-omburtamab), defined as: a. Hemoglobin ≥8 g/dL b. White blood cell count ≥1000/μL. c. Absolute neutrophil count ≥1000/μL d. Platelet count ≥75 000/μL. 9. Acceptable liver function prior to first dosing, defined as: a. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × upper limit of normal (ULN) b. Bilirubin ≤1.5 × ULN. 10. Acceptable kidney function prior to first dosing, defined as: a. Estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m2, calculated by the 2009 revised Bedside Schwartz Equation. 11. Written informed consent from legal guardian(s) and/or child obtained in accordance with local regulations. Pediatric patients must provide assent as required by local regulations. |
|
E.4 | Principal exclusion criteria |
1. Obstructive or symptomatic communicating hydrocephalus as determined by Ommaya patency/CSF flow assessment. 2. Any tumor lesion measuring >15 mm in the smallest diameter. 3. Ventriculoperitoneal (VP) shunts without programmable valves. Ventriculo-atrial or ventriculo-pleural shunts. 4. Grade 4 nervous system disorder. Stable neurological deficits due to brain tumor or surgery and hearing loss are allowed. 5. Uncontrolled life-threatening infection. 6. Received radiation therapy (focal or cranio-spinal irradiation), systemic or intrathecal cytotoxic chemotherapy, or immunotherapy (including monoclonal antibodies; corticosteroids not included) less than 3 weeks prior to the Dosimetry Dose (or until recovery from clinically significant adverse events). Received nitrosoureas less than 6 weeks prior to the Dosimetry Dose. 7. Received any prior anti-B7-H3 treatment. 8. Non-hematologic organ toxicity Grade 3 or above; specifically, any renal, cardiac, hepatic, pulmonary, and gastrointestinal system toxicity. 9. Other significant disease or condition that in the investigator's opinion would exclude the patient from the trial. 10. Females of childbearing potential who are pregnant, breast feeding, intend to become pregnant, or are not using highly effectiven contraceptive methods or males who are not using highly effective contraceptive methods. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of Part 1 is number of DLTs (dose-limiting toxicity). The primary endpoint of Part 2 is number and severity of TEAEs (treatment-emergent adverse event). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Part 1: At the end of 5 week Cycle. Part 2: Analysis with occur after database lock |
|
E.5.2 | Secondary end point(s) |
Part 1 •Lutetium-177 activity in blood and CSF including derivation of best-fit uptake and/or clearance parameters (maximum count, elimination half life) of time-activity curves and residence times (i.e., cumulated activity in µCi·h/g). •Whole-body, organ, blood, and CSF radiation dosimetry. •PK profile of 177Lu-DTPA-omburtamab in serum and CSF.
Part 2 •PK profile of 177Lu-DTPA-omburtamab in blood and CSF. •Response, as defined by the RAPNO criteria (as determined from MRI assessments, neurological examination, and CSF cytology). •ORR, calculated as the proportion of all evaluable patients achieving a response (PR or CR) as best overall response at end of Cycle 1 and Cycle 3, EOT Visit, and at each Follow-up Visit. •Investigator-assessed DoR, defined as the time from first response (CR or PR) to progression. •PFS, defined as the time from first treatment to date of leptomeningeal progression or death from any cause, whichever comes first. •OS defined as the time from first treatment to date of death |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Part 1: at the EOT Visit Part 2: at end of Cycle 1 and Cycle 3, EOT Visit, then 26, 39, and 52 weeks post first dose, followed by 78 and 104 weeks post first dose of 177Lu-DTPA omburtamab. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Dosimetry, Dose-escalation and Expansion Cohort Trial |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Dose-escalation and Expansion Cohort Trial |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
United States |
Denmark |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 22 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 26 |